392 related articles for article (PubMed ID: 27713145)
1. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
5. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
6. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
8. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
10. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
11. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M
Oncology; 2014; 86(1):33-43. PubMed ID: 24401539
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
[TBL] [Abstract][Full Text] [Related]
14. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
[TBL] [Abstract][Full Text] [Related]
16. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
[TBL] [Abstract][Full Text] [Related]
17. Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.
Lacerenza S; Ciregia F; Giusti L; Bonotti A; Greco V; Giannaccini G; D'Antongiovanni V; Fallahi P; Pieroni L; Cristaudo A; Lucacchini A; Mazzoni MR; Foddis R
Cancer Genomics Proteomics; 2020; 17(3):225-236. PubMed ID: 32345664
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
19. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
20. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]